Mail

UK markets close in 3 hours 49 minutes

FTSE 100
8,119.03
+40.17(+0.50%)
FTSE 250
19,813.75
+211.77(+1.08%)
AIM
755.41
+2.29(+0.30%)
GBP/EUR
1.1672
+0.0016(+0.13%)
GBP/USD
1.2517
+0.0006(+0.05%)
Bitcoin GBP
51,264.38
+265.29(+0.52%)

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

GC Biopharma Corp. (006280.KS)

KSE - KSE Delayed price. Currency in KRW

Add to watchlist

111,900.00

+800.00

(+0.72%)

At close: 03:30PM KST

Currency in KRW

Valuation measures⁴

Market cap (intra-day)	1.27T
Enterprise value	1.94T
Trailing P/E	21.15
Forward P/E	17.54
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	0.78
Price/book (mrq)	0.98
Enterprise value/revenue	1.19
Enterprise value/EBITDA	25.07

Trading information

Stock price history

Beta (5Y monthly)	1.09
52-week change ³	-10.11%
S&P500 52-week change ³	21.08%
52-week high ³	134,300.00
52-week low ³	93,000.00
50-day moving average ³	117,842.00
200-day moving average ³	113,956.50

Share statistics

Avg vol (3-month) ³	20.77k
Avg vol (10-day) ³	13.01k
Shares outstanding ⁵	11.41M
Implied shares outstanding ⁶	11.45M
Float ⁸	5.45M
% held by insiders ¹	51.45%
% held by institutions ¹	12.75%
Shares short ⁴	N/A
Short ratio ⁴	N/A
Short % of float ⁴	N/A
Short % of shares outstanding ⁴	N/A
Shares short (prior month ) ⁴	N/A

Dividends & splits

Forward annual dividend rate ⁴	1500
Forward annual dividend yield ⁴	1.35%
Trailing annual dividend rate ³	N/A
Trailing annual dividend yield ³	N/A
5-year average dividend yield ⁴	0.95
Payout ratio ⁴	1,080.25%
Dividend date ³	N/A
Ex-dividend date ⁴	27 Dec 2023
Last split factor ²	1.05:1
Last split date ³	07 Jun 2013

Financial highlights

Fiscal year

Fiscal year ends	31 Dec 2023
Most-recent quarter (mrq)	31 Dec 2023

Profitability

Profit margin	-1.64%
Operating margin (ttm)	-2.21%

Management effectiveness

Return on assets (ttm)	0.82%
Return on equity (ttm)	-1.27%

Income statement

Revenue (ttm)	1.63T
Revenue per share (ttm)	142,497.41
Quarterly revenue growth (yoy)	-1.60%
Gross profit (ttm)	N/A
EBITDA	109.81B
Net income avi to common (ttm)	-26.63B
Diluted EPS (ttm)	N/A
Quarterly earnings growth (yoy)	N/A

Balance sheet

Total cash (mrq)	55.51B
Total cash per share (mrq)	4,863.34
Total debt (mrq)	724.02B
Total debt/equity (mrq)	47.02%
Current ratio (mrq)	1.20
Book value per share (mrq)	N/A

Cash flow statement

Operating cash flow (ttm)	-5.47B
Levered free cash flow (ttm)	-166.64B